

**The Art and Science of Managing the New Melanoma Landscape**  
**Case Based Discussion**  
**February 12, 2022**  
**8:00 am - 2:30 pm**  
**Virtual**

**Target Audience:**

Specialties: Melanoma/Skin Cancers  
Professions: Physician (MD or DO), Nurse/APN, Physician Assistant

**Description:**

This case-based, panel discussion will illustrate the application of new approaches to the treatment of melanoma and non-melanoma skin cancers. It will provide learners with practical and useful examples of how to best manage and treat patients presenting with these diseases.

**Learning Objectives:**

1. Utilize emerging data about the potential indications, safety, and efficacy of adjuvant therapy for patients with high-risk clinically localized melanoma
2. Describe the rationale for neoadjuvant therapy for patients with stage III melanoma and the prognostic significance of the pathological response to treatment
3. Summarize treatment options for patients with stage IV melanoma, and the patients that are not served well by currently available treatments
4. Describe the differences in the presentation and diagnosis of the various nonmelanoma cutaneous cancers (BCC, SCC, Merkel Cell Carcinomas).
5. Examine the indications for immunotherapy in nonmelanoma skin cancers, and the subtleties in response patterns and outcomes.

**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 5.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Commercial Support:**

No commercial support has been received for this activity.

**Disclosure:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Vinodh A. Kumar, MD	CE Reviewer	Nothing to disclose
Rodabe N Amaria, MD	Co-Director, Faculty	Grant or research support-Bristol-Myers Squibb Company Grant or research support-Lovance Grant or research support-Merck Sharp & Dohme Corp. (any division) Grant or research support-Novartis Pharmaceuticals Corporation Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lovance Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation
Allison Baring, CMP	Other planning committee member	Nothing to disclose
Michael A Davies, MD, PhD	Co-Director, Faculty	Grant or research support-Pfizer Inc.  Paid consultant-ABM Therapeutics Paid consultant-Apexigen Paid consultant-Bristol-Myers Squibb Company Paid consultant-Novartis Pharmaceuticals Corporation Paid consultant-Pfizer Inc.  Paid consultant-Roche
Devarati Mitra, MD, PhD	Co-Director, Faculty	Nothing to disclose
Kelly Nelson, MD	Co-Director, Faculty	Nothing to disclose
Merrick I Ross, MD, FACS	Co-Director, Faculty	Nothing to disclose
Carlos A Torres Cabala, MD, FCAP, FASCP	Co-Director, Faculty	Nothing to disclose
Michael K. Wong, MD, PhD, FRCPC	Co-Director, Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Adagene Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-EMD Serono Inc.  Membership on Advisory Committees or Review Panels, Board Membership, etc.-ExiCure Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division) Membership on Advisory

		Committees or Review Panels, Board Membership, etc.-Pfizer Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc.
Phyu Aung, MD, PhD	Faculty	Nothing to disclose
Ahsan Farooqi, MD, PhD	Faculty	Nothing to disclose
Jeffrey Gershenwald, MD	Faculty	Consulting Fee-Merck Sharp & Dohme Corp. (any division)   Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)
Ryan Goepfert, MD	Faculty	Nothing to disclose
Neil D Gross, MD	Faculty	Grant or research support-Regeneron Pharmaceuticals, Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.-PDS Biotechnology   Paid consultant-Dragonfly Therapeutics   Paid consultant-Genzyme Corporation   Paid consultant-Intuitive Surgical, Inc.
Emily Keung, MD	Faculty	Nothing to disclose
Jennifer Mcquade, MD	Faculty	Honoraria-Merck Sharp & Dohme Corp. (any division)
Michael Migden, MD	Faculty	Advisor-Regeneron Pharmaceuticals, Inc.   Advisor-Replimune   Advisor-Sanofi Genzyme   Advisor-Sun pharmaceuticals
Priyadharsini Nagarajan, MD, PhD	Faculty	Nothing to disclose
Hussein Tawbi, MD, PhD	Faculty	Consulting Fee-Boxer Capital   Consulting Fee-Bristol-Myers Squibb Company   Consulting Fee-Eisai, Inc.   Consulting Fee-Genentech, Inc.   Consulting Fee-Iovance   Consulting Fee-Karyopharm Therapeutics   Consulting Fee-Merck Research Laboratories and the Office of the Chief Medical Officer Grants   Consulting Fee-Novartis Pharmaceuticals Corporation   Consulting Fee-Pfizer Inc.   Grant or research support-Bristol-Myers Squibb Company   Grant or research support-Genentech, Inc.   Grant or research support-GlaxoSmithKline   Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants   Grant or research support-Novartis Pharmaceuticals Corporation